ReviewCardiac failure review2025
Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions.
Review in Cardiac failure review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- C-reactive protein-to-albumin ratio and the mortality of patients with heart failure: a meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Prognostic models in populations with heart failure: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Evaluating the efficacy of dual-task training in older patients with chronic heart failure and comorbid cognitive frailty: a protocol for a randomized controlled trial.BMC geriatrics · 2026Trial
- Therapies for Heart Failure: Clinical Updates and Perspectives.Journal of clinical medicine · 2026Article
- Muscle and Bone Implications of GLP-1 Receptor Agonists and Fragility Fractures in Older Adults With Diabetes.Journal of cachexia, sarcopenia and muscle · 2026Article
- Mapping interventions addressing frailty and associated outcomes in people with heart failure: a scoping review.BMJ open · 2026Article
- Frail to Fail: More Support for Less Reserve-Can Clinical Frailty Scale Predict Path to Liberation?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026Article
- Associations Between Gut Microbiota and Mitochondrial Metabolites, with Growth Differentiation Factor-15 as a Marker of Oxidative Stress in Heart Failure vs. Healthy Ageing.Antioxidants (Basel, Switzerland) · 2026Article
- Physical Frailty Versus the MECKI Score in Risk Stratification of Patients with Advanced Heart Failure: Simpler Measure, Similar Insights?Journal of clinical medicine · 2026Article
- Clinical Pharmacology of Heart Failure in Frailty.European cardiology · 2026Review
- Finding and Managing Heart Failure Earlier: Why Enhancing Primary Care Teams to Apply More Definitive Surveillance is the Solution.Cardiac failure review · 2026Review
- Frailty Meets Cardio-oncology: A New Frontier in Personalised Cancer Care.European cardiology · 2026Review
- Risk Stratification Tools in Acute Heart Failure and Their Roles in Personalized Follow-Up.Journal of clinical medicine · 2025Review
- Motor Imagery Training Improves Interoception and Satisfaction with Performance.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is common among heart failure (HF) patients and linked to increased risk of adverse outcomes. Contributing factors include inflammation, sarcopenia and neurohormonal issues which diminish physiological reserves and accelerate the decline of health. Managing frailty in HF requires a multidisciplinary approach to address physical, nutritional and pharmacological needs. Structured exercise and dietary support can improve physical function, while careful medication management, especially with polypharmacy, reduces frailty-related risks. Telemedicine and wearable tech facilitate continuous monitoring and timely intervention, especially for those in remote areas. Future research should develop standardised frailty assessment tools specific to HF, enhancing risk stratification and personalised care. Studies on underlying mechanisms, such as inflammation and mitochondrial dysfunction, could lead to new therapies. Addressing socioeconomic factors can also improve care equity. This review summarises the mechanisms, clinical characteristics and impact of frailty on HF, highlighting challenges in treatment and opportunities for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.